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INTRODUCTION
Of the approximately 44,000 women who die of breast
cancer annually in the United States, one-quarter will pres-
ent with stage IV disease and the remainder will develop
metastases some time following their primary therapy. More
than three decades of single agent and combination chemo-
therapy have produced minimal impact on the expected sur-
vival of patients with stage IV breast cancer [1–4]. Dose
escalation without hemopoietic stem cell support has also
resulted in little change in outcome [5,6]. High-dose
chemotherapy with hemopoietic stem cell transplantation
(HSCT) for patients with breast cancer has led to durable
remissions in only 15–20% of patients with chemosensitive
disease [7–13].
Since substantial laboratory and clinical data on breast
cancer indicate a high degree of primary chemotherapy
resistance, we hyphothesize that the relatively low dose-
intensity two- and three-drug ablative regimens may lack
maximal efficacy in this disease [14–17].
In this study, 158 women with stage IV breast cancer,
previously treated with a variety of salvage therapy pro-
grams, were prepared for transplant with a new four-drug
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ABSTRACT
High-dose chemotherapy and autologous hemopoietic stem cell transplantation (HSCT) may provide durable pro-
gression-free survival in some patients with stage IV breast cancer (S4Brca). We have studied a new four-drug inten-
sive preparative regimen with HSCT in a group of 158 women with S4Brca to define the risk and potential benefit of
this regimen in this patient population. From May 1988 through May 1997, 158 women with S4Brca at a single cen-
ter were treated with cisplatin, etoposide, thiotepa, and cyclophosphamide (PETCy) plus autologous HSCT. Eligible
patients were also treated with posttransplant involved-field radiation therapy. Patients with estrogen-receptor posi-
tive tumors not previously treated with tamoxifen also received this therapy for 5 years following transplantation. All
patients experienced significant toxicity requiring blood-product support and parenteral nutrition. Eighteen patients
(11%) died of regimen-related toxic events. With a median follow-up of 540 days for surviving patients, a retrospec-
tive Kaplan-Meier analysis projects an overall survival of 38 6 8.5% (95% CI) at 890 days with a maximum follow-up
of 8.8 years. For 52 patients in sensitive relapse, the median event-free survival time is 767 days, with 46.2 6 15.3%
(95% CI) predicted to be alive at 884 days with a maximal follow-up of almost 9 years. Nearly one-half of patients in
this study with S4Brca in sensitive relapse have experienced durable remissions following PETCy ablation and
HSCT. Although toxicity is significant, the PETCy regimen produces a favorable balance between efficacy (event-
free survival) and treatment failure (relapse 1 regimen-related toxic death) compared with published results. These
data suggest that within the high-dose range for preparative therapy, a steep dose–response may exist for breast can-
cer. Trials comparing the dose intensity of preparative regimens are warranted.
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intensive tumor-ablative chemotherapy. We describe the
outcome of this treatment in these patients and discuss its
impact on current and future trials in this field.
MATERIALS AND METHODS
Patients
One hundred and fifty-eight women with stage IV
breast cancer were referred to our center for consideration
of transplant therapy from January 1988 through January
1997  (Table 1). Eligibility initially included patients aged
#55 years. In January 1991, the eligibility age was changed
to #65 years. Patients were excluded if there was significant
major organ system dysfunction (left ventricular ejection
fraction ,45%; diffusion capacity ,60%; creatinine clear-
ance ,50 cc/minute; liver transaminases .3 times normal).
Early in the study, patients with tumor infiltration of the
bone marrow space were allowed to enroll if the postsal-
vage therapy marrow biopsy showed no tumor. When nine
of nine such patients showed early relapse in the marrow
following transplant, we excluded such patients from subse-
quent enrollment in the study (from January 1991). These
nine patients are, however, included in this analysis.
Patients with central nervous system metastases and
patients unable to provide written informed consent were
also excluded. Patients were carefully counseled about
alternative therapies, risks, and benefits using consent
forms approved by the institutional review board on experi-
mentation in human subjects.
Salvage chemotherapy and hemopoietic stem cell
collection
Salvage therapy recommendations for each patient were
based on prior treatment history and the relapse-free inter-
val from primary therapy. A prior treatment history of
tamoxifen precluded its use after transplant in patients with
hormone–receptor positive tumors. All patients had marrow
or peripheral blood hemopoietic stem cells (PBHSC) or
both collected after at least three cycles of salvage chemo-
therapy. When PBHSC were collected, granulocyte-colony
stimulating factor (G-CSF) at 5–10 mg/kg was given subcu-
taneously for 4–5 days before collection. Early in the study,
a target dose of 1–2 3 108/kg mononuclear cells was collect-
ed from the marrow. When PBHSC were used, a target
dose of 8 3 108/kg mononuclear cells were collected. Later,
when flow cytometric CD341 cell enumeration became
available, we targeted 1.5–3.0 3 106/kg CD341 cells for
transplantation. Three million CD341 cells per kilogram of
ideal body weight is our current standard.
Assessment of tumor response
The assessment of a tumor’s response to chemotherapy
was done using conventional radiological techniques to
measure bidimensional diameters. Patients with bone-only
metastases posed the greatest problem in objectively
assessing response. Since 1995, we have used positron
emission tomography scan with radiolabeled fluo-
rodeoxyglucose as a complement to plain film or bone scan
or both. Patients were regarded as having a sensitive
relapse if salvage therapy resulted in a 50% or greater
regression of measurable disease.
Medical management of the patients
All patients were admitted to the Adult Bone Marrow
Transplantation Unit at the University of Iowa Hospitals
and Clinics for administration of the high-dose chemo-
therapy and management of the period of pancytopenia.
Rooms were HEPA-filtered, and neutropenic patients were
cared for using reverse isolation precautions. Patients
received prophylactic, broad-spectrum antibiotics including
antifungal coverage when they became neutropenic; these
were discontinued when neutrophils were greater than 500
cells per microliter. All blood products were irradiated and
filtered but not screened for cytomegalovirus before admin-
istration. Hemopoietic stem cells were cryopreserved in
dimethyl sulfoxide using a programmable freezer and stored
in liquid nitrogen. At the time of infusion, individual bags of
cells were thawed one at a time in a 40oC waterbath and
infused over 5 minutes after premedication with steroid
(prednisone 1 mg/kg) and diphenhydramine (50 mg).
Patients were selected to receive posttransplantation radi-
ation therapy if they had not previously received radiation to
sites of metastatic disease and if there were three or fewer
areas requiring radiation, each of which could be technically
included in an involved-field port. Areas showing complete
resolution of disease by posttransplant staging methods were
treated with 3000–5000 cGy over 4–5 weeks, depending on
the tolerance of normal tissues included in the port. If salvage
therapy produced a partial response, an additional 1000–1500
cGy was given. Radiation was started when the neutrophils
Table 1. Characteristics of 158 patients on-study
Characteristic Result
Median age (years) 43 (range 23–62)
Disease at relapse
Sensitive 52 (33%)
Resistant 88 (56%)
Indeterminate 18 (11%)
Hormone receptor
Positive 60 (38%)
Negative 84 (53%)
Unknown 14 (9%)
Metastases
Single organ 94 (59%)
Skin nodule 12 (7.6%)
Regional nodes 26 (16%)
Bone 30 (19%)
Lung 20 (12.7%)
Liver 6 (3.8%)
$2 organ involvement 64 (41%)
Median time to relapse from
primary therapy 747 days (range 138–3495 days)
Number receiving anthracycline
in salvage therapy 82 (52%)
Number receiving posttransplant
radiation 43 (27%)
Number
Marrow HSC 68 (43%)
Marrow 1 PBHSC 8 (5%)
PBHSC only 82 (52%)
HSC, hematopoietic stem cells; PBHSC, peripheral blood hematopoietic
stem cells.
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were .1000 cells/mL and the platelets .50,000/mL; in most
cases this was 4–8 weeks from transplantation.
For at least the first 3 months following discharge from
the transplant unit, all patients were maintained on acyclovir
and trimethoprim-sulfamethoxazole prophylaxis.
Preparative therapy
Table 2 displays the preparative therapy regimen used. It
had been developed in a stepwise fashion through a phase I
trial [18]. Toxicity in this study was evaluated according to
Bearman et al. [19].
Cisplatin at 45 mg/m2 was diluted in 250 mL of 3%
NaCl and infused over 60 minutes, beginning at 8:00 PM
with concurrent normal saline hydration at 250 mL per
hour. Etoposide at 600 mg/m2 was diluted in D5 1/2 normal
saline at 0.4 mg/mL and infused over 6 hours before the cis-
platin. Both the cisplatin and etoposide were given from
Days –9 through –6. Thiotepa at 480 mg/m2 was given as a
continuous infusion over 48 hours beginning on Day –5.
Cyclophosphamide was infused at 3000 mg per hour begin-
ning at 8:00 PM on Days –2 and –1. It was given with con-
current systemic hydration and irrigation of the bladder
with normal saline; mesna was not used. Early in the study,
cyclophosphamide was dosed at 80 mg/kg; in the latter 5
years it was dosed at 3200 mg/m2.
For this study, chemotherapy dose was based on body
surface area, calculated using the patient’s actual body
weight unless it was 25% greater than or less than the ideal
body weight. In such cases, an adjusted body weight was
used, calculated by adding to (or subtracting from) the ideal
body weight 50% of the difference between the actual and
the ideal body weights.
Statistical analysis
All statistical analyses were done retrospectively with
BMDP software (BMDP Statistical Software, Los Angeles,
CA). Where event-free analyses were done, an event was
defined as relapse of the patient’s breast cancer or death
from any cause. Survival curves were compared by the gen-
eralized Wilcoxon’s test.
Variables with a p value ,0.1 were analyzed by a step-
wise regression of the Cox proportional hazards model, with
the assumption that the multiplicative relationship between
the underlying hazard function and the log–linear function
of covariates does not depend on time, and that the effect of
covariates upon the hazard function is log–linear. For this,
covariates were entered or removed on the basis of the max-
imum partial likelihood ratio method, with 0.1 as the limit
of significance to enter and 0.15 to remove.
RESULTS
From May 1988 through May 1997, 158 women with
stage IV breast cancer were enrolled into this study (Table 1).
Through the first half of the study, patients were enrolled
regardless of their response to salvage therapy. During the
latter half of the study, however, a much greater emphasis was
placed on using a .50% reduction in tumor measurements as
a determinant of acceptance for transplantation. Fifty-two
patients had sensitive relapses with $50% reduction in tumor
size with salvage therapy, whereas in 18 patients the tumor
size was not evaluable—in most cases because of resection of
chest-wall or nodal disease for diagnostic purposes. Eighty-
eight patients had ,50% response to salvage therapy. Ninety-
eight patients (62%) were treated with a doxorubricin-con-
taining regimen as their sole salvage therapy before trans-
plant. Twenty-eight patients (18%) received two or more dif-
ferent treatment regimens before transplant.
Toxicity
Toxicity for this regimen was significant, with 11% of
patients experiencing a fatal toxicity. Table 3 shows the dif-
ferent forms of fatal toxicity that occurred. The median age
of patients dying of toxicity was 44 years (range 36–60), only
1 year older than the median age of the entire group. Table 4
shows nonfatal grade II or III toxicity. Gastrointestinal toxic-
ity was the most significant nonfatal toxicity, causing 80% of
patients to require parenteral nutrition and intravenous anal-
gesic narcotics. Severe thrombocytopenia presented in 19
patients as a refractory state, most commonly recognized by
a sudden onset during the several days following the initial
signs of graft function. Platelet counts less than 10,000 per
microliter were refractory to transfusion with multiple ran-
dom donors, in vitro cross-matched platelets, and HLA-
matched platelets. In the majority of patients, antiplatelet
antibodies could not be identified. This state resolved as
autologous platelet production ensued. The two patients with
fatal CNS bleeds had refractory, severe thrombocytopenia.
Table 2. PETCy preparative therapy
cisPlatin X X X X
Etoposide X X X X
Thiotepa X X
Cyclophosphamide X X
HSCT X
Day –9 –8 –7 –6 –5 –4 –3 –2 –1 0
X is the drug dosage as follows: cisPlatin, 45 mg/m2 over 1 hour beginning at
8:00 PM; etoposide, 600 mg/m2 over 6 hours beginning at noon; thiotepa, 480
mg/m2 as a 48-hour infusion beginning at 8:00 AM; cyclophosphamide 3200
mg/m2 at 3000 mg/hour beginning at 8:00 PM. Hemopoietic stem cells
(HSCT) were transplanted on Day 0.
Table 3. Fatal regimen-related toxicity in 18 patients (11%)
Toxicity Number of patients
Heart failure 3
CNS hemorrhage 2
Hyperammonemia 1
Pulmonary hemorrhage 2
Pulmonary DAD 2
Hemolytic-uremic syndrome 1
Infection 7
Gram positive (n521 patients) 1
Gram negative (n528 patients) 2
Fungal (n58 patients) 2
Culture negativea 2
aClinical picture was most compatible with sepsis. 
CNS, central nervous system; DAD, diffuse alveolar damage.
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Resolution of neutropenia (neutrophils $500 cells/mL)
and thrombocytopenia (platelets .25,000 cells/mL)
occurred at a median of 22 and 28 days posttransplant when
marrow alone was used. When cytokine-primed PBHSC
were used with posttransplant G-CSF, the median recovery
times were 13 (p ,0.001) and 28 days posttransplant,
respectively. The median length of hospitalization for those
who received marrow transplants was 42 days, and for those
who received PBHSC it was 32 days.
Response to therapy and survival
One hundred and forty patients had disease that was ret-
rospectively assessed for response to salvage and preparative
chemotherapy. The remaining 18 had no evaluable disease
due to resection for diagnosis. Of the 52 patients with
chemosensitive disease, 23 were in complete remission
before transplant. One hundred and seventeen patients were
thus evaluable for response to the ablative therapy. Restag-
ing studies done 40–100 days from transplant showed com-
plete remission in an additional 99 patients (85%). The
Kaplan-Meier projection for this group for relapse-free sur-
vival at 9 years is 35% (data not shown). Figure 1 shows the
Kaplan-Meier projection of overall survival for the entire
cohort of 158 patients. Figure 2 shows the projected event-
free survival for the entire cohort.
Figures 3 and 4 show the overall survival and event-free
survival projections, respectively, for the 140 patients whose
disease could be evaluated for response to salvage chemo-
therapy. Response to salvage chemotherapy appears to
define two groups of patients who have a significantly dif-
ferent long-term outcome with this treatment approach
(curve A represents patients with $50% tumor regression
with salvage therapy; curve B those who had ,50% tumor
regression). Similar analyses for predictors of disease-free
survival were done for hormone receptor status, number of
organs involved with metastases, skin or lymph node dis-
ease, treatment with posttransplant radiation, source of
stem cells, complete remission vs. a .50% response, and
presence of doxorubricin in the salvage therapy regimen. In
univariate analyses, a significant advantage in event-free
Table 4. Nonfatal grade II and III toxicitya
Organ system Toxicity grade Number of patients (%)
Central nervous system
Altered mentation 2 5 (3.2)
3 10 (6)
Ototoxicity 2 1 (,1)
Peripheral neuropathy 2 2 (1)
Cardiovascular
Arrhythmia 2 8 (5)
LV dysfunction 2 6 (4)
Pulmonary
Hemorrhage 2 2 (1)
2 2 (1)
Gastrointestinal
Stomatitis 2 126 (80)
Diarrhea 2 33 (21)
3 2 (1)
Pancreatitis 3 1 (,1)
Renal
Reduced GFR 2 5 (3)
3 2 (1)
Hemorrhagic cystitis 2 2 (1)
3 4 (2.5)
Hematologic
Thrombocytopenia b 19 (12)
aToxicity scored according to the methods of Bearman et al. [19].
bSevere, protracted, and refractory thrombocytopenia.
LV, left ventricular; GFR, glomerular filtration rate.
Figure 1. The Kaplan-Meier product-limit estimate of overall survival
For 158 patients with stage IV breast cancer following PETCy preparative therapy and autologous peripheral blood hemopoietic stem cell transplantation, the
Kaplan-Meier product-limit estimate of overall survival (OS) is 38 6 8.8% (95% CI) at 890 days from transplantation. The median survival time was 540
days and the median time of follow-up on surviving patients was 508 days from transplant. The 95% CI on the OS time is 407–766 days.
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survival was found for those patients with metastases to a
single organ. For overall survival, estrogen receptor positiv-
ity and one-organ involvement correlated significantly. In
multivariate analyses, using the stepwise Cox proportional
hazards model, chemosensitivity and estrogen-receptor
positive status of the tumor remained significant positive
variables for survival.
Posttransplant radiation therapy
Forty-three patients received radiation treatment fol-
lowing transplantation. Twenty-six were treated to one field
and 10 received treatment to three fields. Sixteen of these
patients are in a continuing remission (CCR) a median of 26
months from transplant (range 8–91 months), whereas six
additional patients in remission at least 24 months post-
transplant subsequently relapsed. Of the 16 in CCR, 12 had
no evidence of disease at transplant because of a chemother-
apeutic response [3] or surgical resection [9].
DISCUSSION
Breast cancer in its metastatic form—whether there is
local, regional, or distant spread—is almost always a fatal
disease. Data from most large cooperative group trials of
combination chemotherapy for stage IV disease reveal com-
plete remission rates of 3–15%, overall response rates of
40–50%, and median survival times of 12 to 24 months with
,10% of the study group surviving beyond 5 years [2–4,20].
In retrospective analyses, two recent papers have reported
the outcome of patients treated for stage IV breast cancer,
one from a single center and one from the European Organ-
ization for Research and Treatment of Cancer. All patients
met strict eligibility criteria for participation in these multi-
ple sequential clinical trials. Results indicate that from 7 to
17% of patients obtain a complete remission when anthra-
cycline-based therapy is used. Up to 20% of patients who
experience a complete remission with standard chemo-
therapy may remain in remission for .5 years. Three-year
progression-free survival (PFS) for complete responders in
both studies is approximately 30% [1,22].
Recently, a number of investigators have begun to study
high-dose chemotherapy with HSC support. Results report-
ed to date are largely single-center experiences and impossi-
ble to compare. The data suggest with some consistency,
however, that 15–20% of patients with previously untreated
Figure 2. The Kaplan-Meier product-limit estimate of event-free
survival
For 158 patients with stage IV breast cancer following preparative therapy
with PETCy and autologous peripheral blood hemopoietic stem cell transplan-
tation, the Kaplan-Meier product-limit estimate of event-free survival (EFS)
is 28.5 6 8.1% (95% CI) at 724 days posttransplant. The median EFS time
is 334 days and the median follow up time on nonrelapsed patients is 416
days. The 95% CI for the EFS time is 249–376 days.
Figure 4. The Kaplan-Meier product-Limit estimate for event-free
survival
For 52 patients with sensitive relapse (curve A), the event-free survival (EFS)
is 46.2 6 15.3% (95% CI) at 928 days vs. 11.4 6 10.6% (95% CI) at 708
days for 88 patients with resistant relapse (curve B). The median EFS time
for patients represented on A is 766 days with a median follow-up time of 563
days, compared with patients represented on B with a median EFS of 232 days
and median follow-up of 411 days. The respective 95% CIs are 376–1433
days and 193–278 days. Comparison of the two curves by generalized Wilcox-
on’s test reveals p 5 0.0001.
Figure 3. The Kaplan-Meier product-limit estimate of overall 
survival for stage IV breast cancer
For patients who experienced a $50% tumor regression with salvage therapy
(curve A), the Kaplan-Meier product-limit estimate of overall survival for
stage IV breast cancer was 53.9 6 15.9% (95% CI) vs. 20.5 6 9.5% for
those whose tumor showed ,50% regression (curve B). Median survival for
patients with sensitive relapse was 1416 days and for those with resistant
relapse 369 days. p , 0.01 by the generalized Wilcoxon’s test.
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or sensitive relapses may experience relapse-free survival
following high-dose chemotherapy and PBHSC transplant
[7–10,23–28]. Antman et al. [29] have used a transplant reg-
istry to examine survival data on over 2600 patients with
metastatic disease treated with autologous HSCT. For all
patients, a median PFS time of less than 12 months and a 3-
year Kaplan-Meier estimate of a PFS of 20% was found. A
subset of 587 patients in complete remission at the time of
transplant experienced a 32% PFS at 3 years.
Whether the transplant intervention has altered the nat-
ural history of the disease in these patients remains in ques-
tion. The 3-year PFS of patients in complete remission in
both the transplant registry and the EORTC/M.D. Anderson
registries is essentially identical [21,22,29]. Comparisons are
further complicated by the suggestion in two recent papers
that a significant favorable bias may accompany the eligibility
criteria for entering nonrandomized, high-dose chemo-
therapy studies [30,31]. Taken together, with all the inherent
limitations of retrospective analyses, these data do not yet
allow for the interpretation that moderately increased dose-
intensity in stage IV breast cancer patients provides durable
remissions in a larger fraction of complete responders who
undergo transplant than those treated with standard therapy.
In 1988, we initiated a single-arm feasibility study with a
novel four-drug, high-dose chemo-ablative regimen for
patients with stage IV disease. Our goals were to define the
toxicity of this regimen and subsets of patients who might
benefit from this therapy. The University of Iowa Hospitals
and Clinics is a tertiary referral center and, as such, there are
inherent biases in the population of patients seen at this cen-
ter that may have played a role in the outcomes of this study.
At the outset of the study, patients were enrolled regardless
of response to salvage chemotherapy. As the study pro-
gressed and outcomes were monitored, eligibility was altered
to enroll patients whose tumor showed chemosensitivity with
at least a 50% reduction in diameter on salvage therapy.
Moreover, after nine of nine patients with bone marrow
involvement quickly relapsed after transplant, patients with
marrow involvement were excluded from enrollment.
The four-drug PETCy ablative protocol was designed to
maximize its antitumor capacity while an anticipated higher
level of toxicity was accepted. Drugs were selected because of
their reported activity against breast cancer and nonoverlap-
ping toxicity in nonhematologic organ systems (Table 5).
The importance of posttransplant radiation therapy  can-
not be assessed in this study. Its limited use in only 43 of 158
patients speaks to the widespread disease seen in the majority.
Of 46 patients in CCR at the time of this analysis, only 16
had received radiation therapy and 12 of these had no evi-
dence of disease at transplant. Radiation therapy was included
in the protocol because of previous observations that recur-
rent disease tended to occur in sites of previous disease [25].
This treatment program failed in about one-half of
patients with chemosensitive relapse. A small proportion of
those failures was due to fatal toxicity; the remaining was
due to recurrent disease. We consider regimen-related fatal-
ities in the broader context of treatment failure and the nat-
ural history of the disease. In published studies of high-dose
breast cancer therapy from other centers, the dose-intensity
of the preparative therapy is lower and, consequently, the
reported regimen-related toxicity is usually lower, although
registry data indicate a 100-day mortality of 10% [29]. The
overall rate of treatment failure (nearly all due to relapse) of
these approaches, however, is in the 75–80% range. With-
out a randomized comparison between these two approach-
es, the question of whether the increased dose intensity of
the PETCy regimen is more efficacious cannot be resolved.
A corollary issue that is similarly difficult to resolve is
whether the high-dose chemotherapy with HSCT con-
tributed at all to the survival in this group of patients. A
number of authors have expressed a reasonable concern that
the success of many high-dose chemotherapy programs for
patients with breast cancer may result from selecting
patients that might have done well without this therapy
rather than eradicating tumors—a criticism that could apply
to this study as well [42,43]. While this may be a valid con-
cern, we also believe that, for all practical purposes in the
United States, trials comparing transplant therapy to some
form of standard therapy will no longer be accepted by
either patients or practitioners [44,29]. Given the high mor-
tality conferred by stage IV breast cancer, well-designed
studies of high-dose chemotherapy with HSCT are warrant-
ed and should continue. Our current focus is to compare
dose intensity in the higher dose range.
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